scholarly journals Inactive SARS-COV-2 vaccine adverse effects in healthcare workers

2021 ◽  
Author(s):  
Esen SAYIN GÜLENSOY ◽  
Aycan YÜKSEL ◽  
Nalan OGAN ◽  
Aslıhan ALHAN ◽  
Evrim AKPINAR
Keyword(s):  
Adverse Effects ◽  
Healthcare Workers

scholarly journals Neutralizing Anti-SARS-CoV-2 Antibody Titer and Reported Adverse Effects, in a Sample of Italian Nursing Home Personnel after Two Doses of the BNT162b2 Vaccine Administered Four Weeks Apart

Vaccines ◽  
2021 ◽  
Vol 9 (6) ◽  
pp. 652
Author(s):  
Alberto Modenese ◽  
Stefania Paduano ◽  
Annalisa Bargellini ◽  
Rossana Bellucci ◽  
Simona Marchetti ◽  
...  
Keyword(s):  
Nursing Home ◽  
Adverse Effects ◽  
Antibody Titer ◽  
Healthcare Workers ◽  
Vaccination Campaign ◽  
Northern Italy ◽  
High Antibody ◽  
Protective Level ◽  
High Antibody Titer ◽  
Main Factors

Background: The immunization of healthcare workers (HCWs) plays a recognized key role in prevention in the COVID-19 pandemic: in Italy, the vaccination campaign began at the end of December 2020. A better knowledge of the on-field immune response in HCWs, of adverse effects and of the main factors involved is fundamental. Methods: We performed a study on workers at a nursing home in Northern Italy, vaccinated in January–February 2021 with two doses of the BNT162b2 vaccine four weeks apart, instead of the three weeks provided for in the original manufacturer protocol. One month after the second dose, the serological titer of IgG-neutralizing anti-RBD antibodies of the subunit S1 of the spike protein of SARS-CoV-2 was determined. The socio-demographic and clinical characteristics of the subjects and adverse effects of vaccination were collected by questionnaire. Results: In all of the workers, high antibody titer, ranging between 20 and 760 times the minimum protective level were observed. Titers were significantly higher in subjects with a previous COVID-19 diagnosis. Adverse effects after the vaccine were more frequent after the second dose, but no severe adverse effects were observed. Conclusions: The two doses of the BNT162b2 vaccine, even if administered four weeks apart, induced high titers of anti-SARS-CoV-2 neutralizing IgG in all the operators included in the study.

scholarly journals Neutralizing Antibodies Titers and Side Effects in Response to BNT162b2 Vaccine in Healthcare Workers with and without Prior SARS-CoV-2 Infection

Vaccines ◽  
2021 ◽  
Vol 9 (7) ◽  
pp. 742
Author(s):  
José Javier Morales-Núñez ◽  
José Francisco Muñoz-Valle ◽  
Carlos Meza-López ◽  
Lin-Fa Wang ◽  
Andrea Carolina Machado Sulbarán ◽  
...  
Keyword(s):  
Single Dose ◽  
Side Effects ◽  
Adverse Effects ◽  
Antibody Production ◽  
Neutralizing Antibodies ◽  
Healthcare Workers ◽  
Vaccination Program ◽  
Expected Result ◽  
Neutralizing Capacity ◽  
The Usa

The main expected result of a vaccine against viruses is the ability to produce neutralizing antibodies. Currently, several vaccines against SARS-CoV-2 are being applied to prevent mortal complications, being Pfizer-BioNTech (BNT162b2) one of the first to be authorized in the USA and Mexico (11 December 2020). This study evaluated the efficacy of this vaccine on antibody production with neutralizing capacity and its side effects in healthcare workers with and without prior SARS-CoV-2 infection and in a group of unvaccinated individuals with prior COVID-19. The main findings are the production of 100% neutralizing antibodies in both groups after the second dose, well-tolerated adverse effects, the possible presence of immunosenescence, and finally, we support that a single dose of this vaccine in individuals with prior COVID-19 would be sufficient to achieve an immunization comparable to people without prior COVID-19 with a complete vaccination program (2 doses).

scholarly journals Adverse Effects on Work and Daily Life Interference among Healthcare Workers after the First and Second ChAdOx1 and BNT162b2 COVID-19 Vaccine Doses

Vaccines ◽  
2021 ◽  
Vol 9 (8) ◽  
pp. 926
Author(s):  
Chulyong Park ◽  
Joon Sakong ◽  
Seongmin Jo ◽  
Minkeun Kim ◽  
Kiook Baek
Keyword(s):  
General Population ◽  
Adverse Effects ◽  
Healthcare Workers ◽  
Daily Life ◽  
Vaccine Dose ◽  
Multivariate Model ◽  
Factors Associated ◽  
Vaccine Type ◽  
Interaction Term ◽  
Numeric Scale

In this study, we assessed the adverse effects and the work and daily life interference associated with each dose of the ChAdOx1 and BNT162b2 COVID-19 vaccines. Questionnaires were distributed to workers after they received both doses; only those who worked the day after receiving the vaccine were included in the analysis. Overall, 368 ChAdOx1-vaccinated and 27 BNT162b2-vaccinated participants were included. Among the ChAdOx1-vaccinated participants, the incidence of adverse effects was significantly lower after the second dose than after the first dose. Among the BNT162b2-vaccinated participants, however, no differences in adverse effects or work and daily life interference were found between the doses. After the first and second dose, the numeric scale score (0–10) for interference with work was 3.9 ± 2.9 and 1.6 ± 1.9 for the ChAdOx1 and 3.2 ± 2.5 and 3.6 ± 3.0 for the BNT162b2 vaccine, respectively. A similar trend was observed for interference with daily life. Factors associated with work and daily life interference in the multivariate model were age, vaccine dose (first or second), and the interaction term of vaccine type and dose. These results could be used to inform the general population of the adverse effects associated with these vaccinations.

Adverse effects of using masks, sanitizer, and gloves among healthcare workers in a tertiary care center during the COVID-19 pandemic: A questionnaire-based study

2021 ◽  
Vol 17 (3) ◽  
pp. 99
Author(s):  
NamrathaK Narayanan ◽  
Anju Anand ◽  
Midhuna Pradeep ◽  
Nandana Shanavas ◽  
Anuvinda Anil ◽  
...  
Keyword(s):  
Adverse Effects ◽  
Healthcare Workers ◽  
Care Center ◽  
Tertiary Care ◽  
Tertiary Care Center

Risk of Rabies Infection and Adverse Effects of Postexposure Prophylaxis in Healthcare Workers and Other Patient Contacts Exposed to a Rabies Virus–Infected Lung Transplant Recipient

2007 ◽  
Vol 28 (05) ◽  
pp. 513-518 ◽  
Author(s):  
Frauke Mattner ◽  
Cornelia Henke-Gendo ◽  
Andreas Martens ◽  
Christian Drosten ◽  
Thomas F. Schulz ◽  
...  
Keyword(s):  
Adverse Effects ◽  
Transplant Recipient ◽  
Rabies Virus ◽  
Healthcare Workers ◽  
Lung Transplant ◽  
Body Fluids ◽  
Lung Transplant Recipient ◽  
Postexposure Prophylaxis ◽  
Eligibility Criteria ◽  
Lung Transplant Recipients

Background. Rabies virus was inadvertently transmitted to a lung transplant recipient through donor lungs. The patient was given ventilatory assistance and cared for postoperatively for 6 weeks before a diagnosis of rabies virus infection was made. Postexposure prophylaxis (PEP) was offered to potentially exposed healthcare workers (HCWs). Methods. Only HCWs classified as belonging to possible and/or proven contact groups (according to a standardized interview) received PEP. The risk of individual HCWs being exposed to rabies virus was reassessed on the basis of viral concentrations measured in the patient's excretions and body fluids. HCWs who were vaccinated as part of PEP were followed up prospectively according to a standardized procedure. Results. Of 179 HCWs and other patient contacts, 132 met the eligibility criteria for PEP (118 [89.4%] with possible contact and 14 [10.6%] with proven contact with the patient's excretions and/or body fluids). One hundred thirty-one individuals started PEP, and 126 met the inclusion criteria for analysis. Of these, 48 (38%) developed at least 1 adverse effect (8 [6.3%] had fever, 37 [29.4%] had headache, 3 [2.4%] had lymphadenopathy, 17 [13.5%] had dizziness, and 6 [4.8%] had paresthesia). No HCW or other patient contact developed rabies or serious PEP-related adverse effects. Reassessment of the individual's risk of infection as a function of the viral concentration in the patient's excretions and/or body fluids (up to 5.12 × 107 copies/mL) revealed that 103 HCWs (78.0%) had contact with high-risk substances (89 [67.40%] had possible contact and 14 [10.7%] had proven contact). Conclusion. HCWs can be exposed to significant viral concentrations in excretions and/or body fluids from rabies virus-infected lung transplant recipients. Because widespread use of PEP entails the possibility of significant health problems for HCWs considered to be at risk of contracting rabies, applying a rational indication for PEP is crucial.

scholarly journals SAFETY OF HYDROXYCHLOROQUINE FOR COVID-19 PROPHYLAXIS AMONG HEALTHCARE WORKERS: AN OBSERVATIONAL STUDY

2020 ◽  
pp. 55-57
Author(s):  
SANGEETA KHANNA ◽  
NITUL M BEWAL ◽  
AMIT ARORA ◽  
KRISHNA PRASAD G V
Keyword(s):  
Health Care ◽  
Adverse Effects ◽  
Healthcare Workers ◽  
Cross Sectional Study ◽  
Care Staff ◽  
Health Care Staff ◽  
Online Questionnaire ◽  
Cross Sectional ◽  
Systemic Examination ◽  
Harmful Effects

Objective: Indian Council of Medical Research recommended hydroxychloroquine (HCQ) for prophylaxis of COVID‐19 for healthcare workers and the Food and Drug Administration approved its use in the treatment and prophylaxis of COVID‐19 disease. Even though HCQ is adequately tolerated in usual circumstances, still questions about the harmful effects of the drug remain a cause for concern in adults treated with HCQ. The objective of this study was to evaluate the major and minor adverse effects of prophylactic HCQ for COVID-19 among healthcare workers. Methods: Our analysis was intended to analyze HCQ’s adverse drug reaction profile for COVID‐19 prophylaxis in prophylactic doses in health-care staff. This was a cross-sectional study carried out among healthcare workers taking HCQ prophylaxis for COVID‑19. The study was carried out over 08 weeks period from April to May 2020. The data were obtained regarding age, sex, comorbidities, and possible adverse effects. A pretested and validated online questionnaire was provided to the participants to assess the harmful effects that they experienced when taking HCQ. Furthermore, pre and post 8 weeks prophylaxis, individuals underwent general and systemic examination, along with ECG and blood sugar level monitoring. Results: The research group comprised 70 previously healthy and health-care staff. In 70 patients, 27 minor adverse effects were reported (18.9%). Headache was the most frequently reported symptoms followed by nausea and vomiting, itching, and skin rashes. There was no statistically relevant variation in harmful effects due to age or number of doses administered. However, none of the adverse effects was serious or debilitating. Conclusion: With adequate pre-prophylaxis evaluation, health education, and regular monitoring, HCQ prophylaxis is safe and devoid of any serious adverse effects in previously healthy individuals.

scholarly journals Adverse effects of COVID‐19 mRNA‐1273 vaccine: A randomized, cross‐sectional study on healthcare workers with detailed self‐reported symptoms

2021 ◽  
Author(s):  
Renuka Ananth Kalyan Kadali ◽  
Ravali Janagama ◽  
Sharanya Peruru ◽  
Viswanath Gajula ◽  
Rajasekhar R. Madathala ◽  
...  
Keyword(s):  
Adverse Effects ◽  
Healthcare Workers ◽  
Cross Sectional Study ◽  
Sectional Study ◽  
Cross Sectional

scholarly journals Association between Immunoglobulin G Levels and Adverse Effects Following Vaccination with the BNT162b2 Vaccine among Japanese Healthcare Workers

Vaccines ◽  
2021 ◽  
Vol 9 (10) ◽  
pp. 1149
Author(s):  
Jun Otani ◽  
Ryuichi Ohta ◽  
Chiaki Sano
Keyword(s):  
Adverse Effects ◽  
Injection Site ◽  
Immunoglobulin G ◽  
Healthcare Workers ◽  
Adverse Reactions ◽  
Community Hospital ◽  
Cross Sectional Study ◽  
Cross Sectional ◽  
Systemic Symptoms ◽  
Self Administered Questionnaire

The purpose of the study was to assess the association between the amount of immunoglobulin G (IgG) and the duration of adverse effects of COVID-19 vaccinations in the Japanese population. This cross-sectional study was conducted from April 2020 to August 2021 among workers at a community hospital. All participants received two doses of the BNT162b2 vaccine (Pfizer-BioNTech) in March and April 2021. Vaccine side effects were measured using a self-administered questionnaire. Serum anti-SARS-CoV-2 IgG was measured 3 months after vaccination. There was a total of 338 participants (mean age: 44.7 years). The incidence of adverse reactions after vaccination was higher in women. Adverse reactions associated with higher IgG levels included: erythema at the injection site after the first dose; induration and inflammation at the injection site; and systemic symptoms, e.g., fever and headache after the second dose. IgG levels were higher in younger participants. These findings could mitigate fears regarding the mild adverse effects of the COVID-19 vaccine and encourage uptake of the BNT162b2 vaccine.

Sign in / Sign up

Export Citation Format

Share Document